EMBARK Trial VL

Discussion Between Expert Clinicians and Patients on the EMBARK Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg

Details
Matthew Cooperberg, alongside patient advocates Stan Rosenfeld, Bruce Zweig, Nathan Roundy, and Leszek Izdebski, engages in a comprehensive Q&A session with Neal Shore, Stephen Freedland, and Rana McKay. They explore the potential applications of enzalutamide for low-risk prostate cancer patients on active surveillance, referencing findings from the ENACT and EMBARK trials. Dr. Shore emphasizes th...

EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay

Details
Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland an...

The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore

Details
Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free surviva...

Advancing Prostate Cancer Care: The EMBARK Study and Implications for Clinical Practice - Stephen Freedland

Details
Daniel George and Stephen Freedland delve into the EMBARK study, a trial on Enzalutamide for high-risk non-metastatic biochemical recurrence of prostate cancer. They explore the approach of using Enzalutamide, both in combination with Leuprolide and as monotherapy, highlighting its significant impact on metastasis-free survival. The study reveals that combination therapy substantially reduces the...